Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APML3 trial in acute promyelocytic leukemia
ACTRN12607000410459Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 1997
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idarubicin, tretinoin, prednisone, mercaptopurine and methotrexate in Acute promyelocytic leukaemia (APL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Complete remission rate, Actuarial relapse-free survival and 1 more. Started Aug 1997; status: completed.
02
Drugs
idarubicintretinoinprednisonemercaptopurinemethotrexate
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ACTRN12607000410459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000410459.